Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelareorep with Paclitaxel in Advanced Breast Cancer
NCT05519059Phase 1Completed
- Sponsor
- Adlai Nortye
- Start
- Oct 2021
- Primary completion
- Sep 2022
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pelareorep in breast cancer, sponsored by Adlai Nortye. Primary endpoint: Dose Limiting Toxicities at 4 weeks. Started Oct 2021; status: completed.
02
Drugs
pelareorep
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05519059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05519059.